The treatment of invasive fungal infections is limited to a range of drugs from five recognized classes of antifungal therapy and is linked to considerable morbidity and death. In reality, dose-limiting toxicities, medication interactions, and delivery methods frequently place restrictions on the use of currently available antifungal medications. The need for the discovery of new antifungals, especially those with unique modes of action, has arisen from the increased incidence of invasive fungal infections, rising resistance rates, and the practical limits of current treatments. An overview of antifungal drugs at different phases of clinical development is provided in this article. We'll talk about the latest additions to the current family of antifungal medications, which includes the highly bioavailable azole SUBA-itraconazole, the oral amphotericin B cochleate, and the long-acting echinocandin rezafungin, which can be used once a week. We will also evaluate new first-in-class drugs including olorofim, an oral pyrimidine synthesis inhibitor with a broad range of action and an oral formulation, and ibrexafungerp, an oral glucan synthase inhibitor with effectiveness against a variety of resistant fungal isolates. We will also look at several other novel antifungal drugs and classes, such as MGCD290, tetrazoles, and fosmanogepix.